Diverse Pipeline of Candidates Identified

Program

Discovery

Proof of Principle

Lead Optimisation

Pre-Clinical

Phase I

BVX001

Bispecific ADC

Indication: AML

Targets: CD33 x CD7

Multiple Candidates

Bispecific ADCs

Indication: Haem & solid tumour indications

Targets: Undisclosed

BiVictriX Therapeutics Ltd.

 

Bio Hub   |   Alderley Park  |   Alderley Edge   |    Cheshire    |    SK10 4TG   |    UK

 

The OpTIC Centre  |  St Asaph Business Park  |  St Asaph  |   Wales  |   LL17 0JD  |   UK

 

info@bivictrix.com